Mumbai: Zydus Lifesciences Limited's USA office in New Jersey concluded a USFDA inspection of its pharmacovigilance and post-marketing surveillance system with 'nil observations', the company announced on 26 September 2026.
Inspection Details
The onsite inspection was conducted by the United States Food and Drug Administration (USFDA) from 22 September to 25 September 2026.
Read Also
Zydus Lifesciences Extends Sterling Biotech API Deal Deadline, Acquisition Closing Pushed To...
Company Background
Zydus Lifesciences Limited is headquartered in Ahmedabad, India, with its registered office located at 'Zydus Corporate Park'. The company operates in the life sciences sector.
Disclaimer: This story is based on company exchange filings and is for informational purposes only. Investors should evaluate risks before making decisions.
